Onco Actu du 4 juillet 2016

	1. Biologie
Microbiome of breast links to breast cancer [The Evolution and Medicine Review] While there is considerable overlap between the species composition of breast milk and the resident bacteria in the breast ducts, as one might expect, there were several differences found between the breast ductal flora of women with a history of breast cancer and normal women.
Lab-grown tumour could hold key to cancer [The Guardian] British scientists have started work on a revolutionary construction project: building a tumour from its basic biological components.
	4.5 Dép., diag. & prono. - Colorectal
Top 5 reasons people don’t get screened for colorectal cancer [ACS] Interestingly, nearly all unscreened people know that they should be screened. In fact, awareness about colorectal cancer screening recommendations approaches 100 percent.
	5.12 Immunothérapies
Dividing T Cells Inherit Uneven Enzyme Activity - A Potential Target for Improving Cancer Immunotherapy [Johns Hopkins] Mouse studies of “asymmetric division” of immune T cells may also shed light on how stem cells differentiate.
	5.2 Pharma
GSK announces start of phase I oncology study with its ICOS agonist antibody [GSK] ICOS is a co-stimulatory receptor that enhances T-cell responses and results in an increased anti-tumour response from the immune system.
	5.2.3 Pharma - économie
UK healthcare professionals received £340.3 million in benefits from pharma industry in 2015 discloses ABPI [Pharmafile] “We don’t want our neighbours to know what we earn,” said Mike Thompson, the chief executive of industry body Association of the British Pharmaceutical Industry (ABPI) at a media briefing in London, as he launched a new initiative that will put the details of payments received by healthcare professionals in the public domain.
	5.3 Traitements - FDA, EMA,...
Pazdur Named Acting Director of FDA’s New Cancer Center [The Cancer Letter] At the FDA, the patient voice is an integral part of our regulatory decision-making, based on professional responsibility and personal experience. This will continue to be valued in the work of the OCE across oncology-related products.
Biden Announces FDA Center of Excellence [The Cancer Letter] “We don’t have a deadline, and what I’m more interested in doing is making sure that everybody’s voice is heard,” Pazdur said. “One of the first things that I want to do at this point really is to sit down with a review staff.
NICE says 'yes' to degarelix for men with prostate cancer [European Pharmaceutical Review] This announcement comes after a review process lasting over 3 years.
	5.3.4 Traitements - AMM (FDA, EMA)
European Commission Approves Extended Indication For Amgen's Kyprolis Carfilzomib For The Treatment Of Relapsed Multiple Myeloma Patients [Amgen] New Indication Allows Kyprolis to be Used in Combination with Dexamethasone Alone for Appropriate Patients.
	5.4 Traitements - Economie
Gilead hikes price of HIV therapies, other drugs by up to 10 percent [STAT] The prices of the antibiotic Cayston, the chest pain drug Ranexa, and the blood cancer drug Zydelig each went up by 10 percent.
	5.6 ESMO
World GI 2016 Press Release: Anti-Interleukin-1 Alpha Antibody MABp1 Improves Outcomes Significantly Over Placebo [ESMO] Phase III trial finds excellent safety and tolerability.
	6.10 Politiques
Brexit Implications: EU Funding Received by UK Institutions in the Last Ten Years #BrexitScience [Digital Science] The ÜberResearch team did a quick search on Dimensions, their grant database containing more than $1 trillion of historic and current research funding, to see what had been awarded to UK universities by either the European Research Council or the European Commission.
	6.10.1 Politiques (USA)
Biden: What I Learned About Cancer [The Cancer Letter] And the cost of lifesaving drugs is astronomical. We have to come up with a better way. What is the possible justification when a drug a lifesaving drug is brought to market at the time it’s brought to market it costs $26,000 a year, and 15 years later it costs $120,000? Tell me, tell me—tell me, what is the justification for that?
Biden’s Moonshot Goals are Flexible Enough to be Realistic [The Cancer Letter] “The impediment isn’t the lack of the gray matter genius and ingenuity in terms of new drugs, new treatments, etc.,” Biden said at the summit. “It’s all this stuff that gets in the way.”
	6.11 Patients
Well: At the End of Life, What Would Doctors Do? [NY Times] In any event, the public’s interest in the medical treatments that doctors choose must not be allowed to reinforce our culture’s tendency to see dying solely through medical lenses. More to the point is the question, how do dying doctors live?
	6.7.2 Applis
Think Differentially: Apple’s Forward-Thinking Approach to Privacy in iOS 10 [CDT] Apple incorporating differential privacy to improve their products in a privacy-preserving manner will signal that companies can and should design software that is transparent and privacy-protective while still being driven by user data.
	6.9 Controverses
Have 1 in 5 UK academics fabricated data? [Retraction Watch] The survey — of 215 UK academics — estimated that 1 in 7 had plagiarized from someone else’s work, and nearly 1 in 5 had fabricated data.